“Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.” Stephen Y. Chan and Lewis J. Rubin. Eur Respir Rev 2017; 26: 170094. Source: Eur Respir Rev, 27 (147) 175094; 10.1183/16000617.5094-2017 Year: 2018
“Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.” Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown. Eur Respir Rev 2017; 26: 170050. Source: Eur Respir Rev, 27 (148) 175050; 10.1183/16000617.5050-2017 Year: 2018
“Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.” Bridget F. Collins and Ganesh Raghu. Eur Respir Rev 2019; 28: 190022. Source: Eur Respir Rev, 28 (154) 195022; 10.1183/16000617.5022-2019 Year: 2019
“Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?” Irene M. Lang and Hiromi Matsubara. Eur Respir J 2019; 53: 1900843. Source: Eur Respir J, 54 (4) 1950843; 10.1183/13993003.50843-2019 Year: 2019
“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64. Source: Eur Respir Rev 2015; 24: 545 Year: 2015
“Is bronchiectasis really a disease?” Michal Shteinberg, Patrick A. Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051. Source: Eur Respir Rev, 29 (155) 195051; 10.1183/16000617.5051-2019 Year: 2020
“Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.” Irene Lang, Bernhard C. Meyer, Takeshi Ogo, Hiromi Matsubara, Marcin Kurzyna, Hossein-Ardeschir Ghofrani, Eckhard Mayer and Philippe Brenot. Eur Respir Rev 2017; 26: 160119. Source: Eur Respir Rev, 26 (144) 165119; 10.1183/16000617.5119-2016 Year: 2017
“Cellular mechanisms underlying steroid-resistant asthma.” Ridhima Wadhwa, Kamal Dua, Ian M. Adcock, Jay C. Horvat, Richard Y. Kim and Philip M. Hansbro. Eur Respir Rev 2019; 28: 190021. Source: Eur Respir Rev, 28 (154) 195096; 10.1183/16000617.5096-2019 Year: 2019
“Cardiovascular disease and COPD: dangerous liaisons?” Klaus F. Rabe, John R. Hurst and Samy Suissa. Eur Respir Rev 2018; 27: 180057. Source: Eur Respir Rev, 27 (150) 185057; 10.1183/16000617.5057-2018 Year: 2018
“Triple therapy in idiopathic pulmonary fibrosis: an alarming press release.” A.U. Wells, J. Behr, U. Costabel, V. Cottin and V. Poletti. Eur Respir J 2012; 39: 805–806. Source: Eur Respir J 2012; 39: 1552 Year: 2012
“Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD.” Ciro Casanova and Bartolome R. Celli. Eur Respir J 2014; 43: 951–953. Source: Eur Respir J 2014; 43: 1825 Year: 2014
“Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes.” Sabina A. Guler, Joanne M. Kwan, Janice M. Leung, Nasreen Khalil, Pearce G. Wilcox and Christopher J. Ryerson. Eur Respir J 2020; 55: 1900647. Source: Eur Respir J, 55 (3) 1950647; 10.1183/13993003.50647-2019 Year: 2020
“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al . Eur Respir Rev 2019; 28: 190021. Source: Eur Respir Rev, 28 (153) 195021; 10.1183/16000617.5021-2019 Year: 2019
“Haemoptysis due to pulmonary venous stenosis.” Silke Braun, Ivan Platzek, Klaus Zöphel, Matthias Weise, Martin Kolditz, Michael Halank and Gert Hoeffken. Eur Respir Rev 2014; 23: 170–179. Source: Eur Respir Rev 2014; 23: 399 Year: 2014
“Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.” Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776–1784. Source: Eur Respir J 2016; 48: 593 Year: 2016
“Do bacteria have a role in asthma development?” J. Armann and E. von Mutius. Eur Respir J 2010; 36: 469–471. Source: Eur Respir J, 54 (1) 1050414; 10.1183/13993003.50414-2010 Year: 2019
“A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice.” Akihiro Takemasa, Yoshiki Ishii and Takeshi Fukuda. Eur Respir J 2012; 40: 1475–1482. Source: Eur Respir J 2014; 44: 1101 Year: 2014
“Exercise pulmonary haemodynamics: a test in search of purpose.” J. Gerry Coghlan and Harm Jan Bogaard. Eur Respir J 2016; 47: 1315–1317. Source: Eur Respir J 2016; 48: 285 Year: 2016
“The CFTR and EGFR relationship in airway vascular growth, and its importance in cystic fibrosis.” Jay A. Nadel. Eur Respir J 2013; 42: 1438–1440. Source: Eur Respir J 2014; 43: 658 Year: 2013
“Exhaled nitric oxide and the risk of wheezing in infancy: the Generation R Study.” C. Gabriele, V.W. Jaddoe, E. van Mastrigt, L.R. Arends, A. Hofman, H.A. Moll and J.C. de Jongste. Eur Respir J 2012; 39: 567–572. Source: Eur Respir J 2012; 39: 1281 Year: 2012